Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm

Laia Montoliu-Gaya, Sandra Villegas

Producció científica: Contribució a una revistaArticle de revisióRecercaAvaluat per experts

7 Cites (Scopus)

Resum

© 2017 Elsevier Ltd Neurodegenerative disorders are characterized by the progressive accumulation of misfolded protein aggregates that eventually lead to the loss of selected neuronal populations. Immunotherapy has been shown in the recent years as a promising approach for targeting, clearing, and reducing the accumulation of protein aggregates. Alzheimer's disease (AD), which is the most common neurodegenerative disorder, has been the focus of numerous immunotherapeutic studies because the extracellular nature of the amyloid-β (Aβ) peptide. The aim of the current work is to dissect the state-of-the-art of anti-Aβ immunotherapy for AD. The rationale behind anti-Aβ antibodies, what has happened in clinical trials, and which strategies have been designed to avoid side-effects and improve the efficacy of those antibodies are presented.
Idioma originalEnglish
Pàgines (de-a)59-67
RevistaCurrent Opinion in Chemical Engineering
Volum19
DOIs
Estat de la publicacióPublicada - 1 de març 2018

Fingerprint

Navegar pels temes de recerca de 'Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm'. Junts formen un fingerprint únic.

Com citar-ho